Olympus, Shimadzu And Keio University To Establish ¥2 Billion Cancer Research Facility
This article was originally published in PharmAsia News
Executive Summary
Japanese medical device makers Olympus and Shimadzu and Keio University will collaborate in establishing a cancer treatment research and development center in 2010. The center will be the first in Japan to focus on developing less invasive therapies and next generation medical devices and drugs such as ultra-compact robots. Out of the ¥2 billion investment, the Japanese government plans to provide ¥800 million. Two major industrial companies Yokogawa Electric and Hamamatsu Photonics also plan to join in the project. Keio estimates ¥25 billion in economic profit as a result of the new research center. (Click here for more - Japanese language
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.